en.Wedoany.com Reported - ChemT Biotechnology has announced the completion of a total of $5 million in funding, consisting of $1 million in angel investment and $4 million in seed round. The seed round was led by Wavemaker Ventures, with participation from SEEDS (SG Growth Capital, an investment platform under the Singapore Economic Development Board and Enterprise Singapore), and supported by institutions including Wavemaker 360 Health, Draper University Ventures, and the Temasek Life Sciences Accelerator. The funds will be used to expand its AI and experimental infrastructure, aiming to lower the barriers to manufacturing and scaling advanced biologics.
The large-scale production of biologics has long faced structural bottlenecks such as lengthy development cycles, unstable yields, and difficulties in process scale-up, with the core issue being the lack of precise computation and regulation capabilities for cells—these "micro-factories." Unlike traditional AI drug discovery or automation tools, ChemT focuses on embedding intelligence directly into the manufacturing process itself, addressing production-side regulation challenges at the cellular level.
The company's core technology is the CelMo™ platform, an AI virtual cell model trained on billions to trillions of proprietary biological sequencing reads. This platform simulates cellular state changes under manufacturing conditions, genetic variations, and environmental stresses, mapping the dynamic landscape of cells throughout the manufacturing process. Based on this, it identifies target pathways that can improve performance and designs small molecules to guide cell behavior. The flagship small molecule product developed on this platform, Chemplify™, applies the same approach to the T-cell manufacturing process.
In CHO cells (a cell type commonly used for producing antibodies and therapeutic proteins), the platform has achieved a 50% increase in antibody yield and a 40% reduction in production cycle time. In T-cell manufacturing, Chemplify™ has realized a 50% improvement in development speed, a 3-fold increase in scalability, a 60% reduction in cost, and a 10-fold increase in cell expansion yield.
ChemT co-founder and CEO Jie Sun stated that since the company was established about a year and a half ago, it has established commercial collaborations with over 40 pharmaceutical, biotechnology, and CDMO companies globally. Future plans include expanding the CelMo™ platform from CHO cells and T cells to stem cell, NK cell, and HEK cell systems, covering a broader range of intelligent control needs in biomanufacturing. Co-founder and President Dr. Ling Wu noted that clients seek collaboration due to bottlenecks such as lengthy development cycles and scale-up failures, and CelMo™ aims to address these issues by understanding the internal states of cells and performing intelligent interventions. Paul Santos, co-founder and managing partner of Wavemaker Partners, commented that the ChemT team combines deep technical expertise, commercial capability, and capital efficiency, offering manufacturers a faster, lower-cost, and more stable quality approach by precisely regulating cell behavior with small molecules.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
